Table of Contents

company-logo

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Keros Therapeutics Dividend Announcement

• Keros Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Keros Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Keros Therapeutics Dividend History

Keros Therapeutics Dividend Yield

Keros Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Keros Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Keros Therapeutics Financial Ratios

P/E ratio-13.35
PEG ratio0.23
P/B ratio4.55
ROE-41.74%
Payout ratio0.00%
Current ratio19.03
Quick ratio19.03
Cash Ratio18.30

Keros Therapeutics Dividend FAQ

Does Keros Therapeutics stock pay dividends?
Keros Therapeutics does not currently pay dividends to its shareholders.
Has Keros Therapeutics ever paid a dividend?
No, Keros Therapeutics has no a history of paying dividends to its shareholders. Keros Therapeutics is not known for its dividend payments.
Why doesn't Keros Therapeutics pay dividends?
There are several potential reasons why Keros Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Keros Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Keros Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Keros Therapeutics a dividend aristocrat?
Keros Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Keros Therapeutics a dividend king?
Keros Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Keros Therapeutics a dividend stock?
No, Keros Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Keros Therapeutics stocks?
To buy Keros Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Keros Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.